Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: Merck & Co. 16.607, BioNTech 0.114.
Merck & Co. vs BioNTech Net Worth and Market Cap
Merck & Co. (MRK) and BioNTech (BNTX) are peers in Vaccines. Merck & Co. reported revenue of $16.6B as of Q2 2026, compared with $114M for BioNTech. Merck & Co. leads on revenue.
Merck & Co.'s gross margin is 73.5% versus 8.1% for BioNTech. Merck & Co.'s net margin is -8.0% versus -777.3% for BioNTech.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: Merck & Co. +5.1%, BioNTech -59.6%.
- Both made operating losses in their latest quarter: Merck & Co. at a -4.1% margin, BioNTech at -897.8%.
- Merck & Co.'s KPIs on Sterling include Merck Animal Health Livestock vs Companion Animal (Quarterly) and Merck Gardasil China Sales as Printed.
- BioNTech's KPIs on Sterling include Cash, Cash Equivalents, and Security Investments (Quarterly) and COMIRNATY Doses as Printed.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., BioNTech.| Metric | Merck & Co. | BioNTech |
|---|---|---|
| Market Cap | - | - |
| Revenue | $16.61B | $114.00M |
| Cost of Revenue | $4.39B | $105.00M |
| Gross Profit | $12.21B | $9.00M |
| Operating Income | $-683.00M | $-1.02B |
| Net Income | $-1.33B | $-886.00M |
| R&D Expense | $9.74B | $595.00M |
| Earnings Per Share | -$0.54 | -$3.5 |
| Gross Margin | 73.5% | 8.1% |
| Operating Margin | -4.1% | -897.8% |
| Net Profit Margin | -8.0% | -777.3% |
| Free Cash Flow | $4.48B | $-48.00M |
| Cumulative Free Cash Flow | $249.70B | $19.56B |
| Operating Cash Flow | $5.37B | $12.00M |
| Cash & Equivalents | $6.85B | $10.52B |